Jiang Hui, Mao Tangyou, Sun Zhongmei, Shi Lei, Han Xiao, Zhang Yang, Zhang Xiaosi, Wang Jiali, Hu Juncong, Zhang Liming, Li Junxiang, Han Haixiao
School of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Front Microbiol. 2022 Dec 12;13:1001778. doi: 10.3389/fmicb.2022.1001778. eCollection 2022.
Yinchen Linggui Zhugan decoction (YLZD) is an effective and classical traditional herbal prescription for treating the nonalcoholic fatty liver disease (NAFLD) and has been proven to be effective in the regulation of lipid metabolism disorder and attenuate inflammation for a NAFLD rat model. However, the exact underlying mechanism has not been elucidated. In the current study, a NAFLD rat model was established using a high-fat diet (HFD) for 10 weeks, followed by YLZD treatment with 1.92 g/kg/day for 4 weeks to explore the mechanisms of YLZD. Our results showed that YLZD decreased the hepatic lipid deposition, restored the liver tissue pathological lesions, inhibited the expression of oxidative stress, and decreased the inflammatory cytokines levels. Meanwhile, the genes and proteins expressions of SIRT1/Nrf2 signaling pathway together with downstream factors including HO-1 and NQO1 were elevated in the YLZD treated NAFLD rats. For further elaborating the upstream mechanism, short-chain fatty acids (SCFAs) in serum and feces were measured by liquid chromatograph mass spectrometer and gas chromatograph mass spectrometer, and the differences in gut microbiota of rats in each group were analyzed through high-throughput sequencing of 16S rRNA. The results demonstrated that the contents of butyric acid (BA) and total SCFAs in YLZD-treated NAFLD rats were significantly increased in serum and feces. 16S rRNA sequencing analysis illustrated that YLZD intervention led to a modification of the gut microbiota composition, with a decrease of , and the ratio of , as well as the increase in SCFAs-producing bacteria such as , , , and . Spearman rank correlation analysis indicated that BA and total SCFAs were negatively co-related with oxidative stress-related factors and inflammatory cytokines, while they were positively co-related with SIRT1/Nrf2 pathway related genes and proteins. Furthermore, study confirmed that BA effectively reduced oxidative stress by activating SIRT1/Nrf2 signaling pathway in L02 cells. Together, the present data revealed YLZD could ameliorate HFD-induced NAFLD in rats by the modulation of SIRT1/Nrf2 signaling pathway and gut microbiota.
茵陈苓桂术甘汤(YLZD)是治疗非酒精性脂肪性肝病(NAFLD)的一种有效且经典的传统中药方剂,已被证明对NAFLD大鼠模型的脂质代谢紊乱调节和炎症减轻有效。然而,确切的潜在机制尚未阐明。在本研究中,使用高脂饮食(HFD)建立NAFLD大鼠模型10周,随后用1.92 g/kg/天的YLZD治疗4周以探索YLZD的作用机制。我们的结果表明,YLZD减少了肝脏脂质沉积,恢复了肝组织病理损伤,抑制了氧化应激表达,并降低了炎症细胞因子水平。同时,在接受YLZD治疗的NAFLD大鼠中,SIRT1/Nrf2信号通路及其下游因子包括HO-1和NQO1的基因和蛋白表达升高。为进一步阐明上游机制,通过液相色谱 - 质谱仪和气相色谱 - 质谱仪测量血清和粪便中的短链脂肪酸(SCFAs),并通过16S rRNA高通量测序分析每组大鼠肠道微生物群的差异。结果表明,接受YLZD治疗的NAFLD大鼠血清和粪便中丁酸(BA)和总SCFAs含量显著增加。16S rRNA测序分析表明,YLZD干预导致肠道微生物群组成发生改变, 、 减少, 、 的比例降低,以及 、 、 、 等产生SCFAs的细菌增加。Spearman等级相关分析表明,BA和总SCFAs与氧化应激相关因子和炎症细胞因子呈负相关,而与SIRT1/Nrf2通路相关基因和蛋白呈正相关。此外, 研究证实BA通过激活L02细胞中的SIRT1/Nrf2信号通路有效降低氧化应激。综上所述,目前的数据表明YLZD可通过调节SIRT1/Nrf2信号通路和肠道微生物群改善HFD诱导的大鼠NAFLD。